Agios appoints Celgene’s Jacqualyn Fouse as new CEO
pharmafile | September 5, 2018 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | CEO, COO, Celgene, Jacqualyn Fouse, agios
The Massachusetts-based oncology specialist Agios Pharmaceuticals has appointed former Celgene President and COO Jacqualyn Fouse as their new Chief Executive Officer (CEO). She will assume her new role and succeed current, long-time CEO David Schenkein on the 1st of February 2019.
Shennkein, who took on his current role in 2009, is set to transition into the role of Executive Chairman while also serving on the board’s Science & Technology Committee.
“Throughout her career, Jackie has demonstrated the ability to effectively plan for and successfully execute on clinical and commercialization strategies, which will be essential as the company works to further its transition to a sustainable multi-product company,” Agios chairman John Maraganore said in a statement.
Fouse, an Economics graduate from the University of Texas in Arlington, rose through the ranks of Celgene taking on increasingly senior roles between 2010 and 2017. However previously the PhD grad had also led global agribusiness and food company Bunge Limited between 2007 and 2010, in her position as Chief Financial Officer (CFO).
“I would like to thank Jackie for her incredible commitment and dedication to Celgene and the patients we seek to serve worldwide,” said Mark Alles, Chief Executive Officer of Celgene. “On behalf of all Celgene employees, I wish Jackie the best in her retirement.”
While Fouse is well regarded by Wall Street, Agios’ shares have risen by around 40% since the start of last year. The move is likely good news for shareholders as the experienced finance chief is set to focus on expansion in markets outside of the United States and existing drug candidates that are currently in development.
NICE has issued a Final Appraisal Document (FAD) recommending Celgene’s REVLIMID (lenalidomide) as maintenance treatment …
NICE opts to reject Celgene’s Revlimid for newly diagnosed multiple myeloma after an autologous stem cell transplant
It has emerged that NICE has opted to reject Celgene’s Revlimid (lenalidomide) for the maintenance …